一分鐘看懂赤子城科技(09911.HK)2022年中期業績
“出海新勢力”之一赤子城科技(9911.HK)發佈中期業績報吿顯示,公司上半年總收入達13.7億人民幣,同比增長約32.3%;公司所有人應占利潤(歸母淨利潤)約8300萬元,同比增長約121.3%。隨着業務規模擴大,公司持續吸納行業人才,並加大研發投入。截至6月30日,公司員工數量達到733人,與2021年末相比增長32%;其中研發人員達440人,佔整體員工數的60%。上半年公司研發投入約9100萬元,同比增長約70%。
下面讓我們通過一分鐘視頻來了解赤子城科技(09911.HK)2022年中期業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.